Alnylam Pharmaceuticals, Inc.
ALNY
주식 순위
#799
Alnylam Pharmaceuticals, Inc. is a biopharmaceutical company primarily... Alnylam Pharmaceuticals, Inc. is a biopharmaceutical company primarily dedicated to the discovery, development, and commercialization of innovative therapeutic solutions leveraging ribonucleic acid interference (RNAi) technology. Its robust pipeline of RNAi-based treatments addresses a range of critical therapeutic areas, including inherited genetic disorders, cardio-metabolic conditions, hepatic infectious diseases, and central nervous system (CNS) and ocular disorders. Currently, Alnylam offers several approved therapies: ONPATTRO (patisiran) for adults suffering from polyneuropathy associated with hereditary transthyretin-mediated amyloidosis; GIVLAARI for adult patients with acute hepatic porphyria (AHP); and OXLUMO (lumasiran) for primary hyperoxaluria type 1 (PH1). Beyond its commercial portfolio, the company maintains an active development pipeline. Key investigational therapies include givosiran, aimed at adolescent patients with AHP; patisiran, being explored for transthyretin amyloidosis (ATTR) with cardiomyopathy; cemdisiran for complement-mediated disorders; ALN-AAT02 for AAT deficiency-associated liver disease; ALN-HBV02 for chronic hepatitis B virus infection; Zilebesiran for hypertension; and ALN-HSD for non-alcoholic steatohepatitis (NASH). Additionally, other candidates such as Fitusiran for hemophilia and bleeding disorders, Inclisiran for hypercholesterolemia, an expanded indication for lumasiran for advanced PH1 and recurrent kidney stones, and vutrisiran for ATTR amyloidosis (currently in Phase 3 clinical trials) are also progressing. Alnylam also engages in strategic alliances with other pharmaceutical leaders. Notable collaborations include those with Regeneron Pharmaceuticals, Inc., focused on discovering and developing RNAi therapeutics for ocular and CNS targets, and with Sanofi Genzyme for broader RNAi therapeutic development and commercialization efforts. Further licensing and partnership agreements are in place with entities such as Novartis AG, Vir Biotechnology, Inc., Dicerna Pharmaceuticals, Inc., Ionis Pharmaceuticals, Inc., and PeptiDream, Inc. Established in 2002, Alnylam Pharmaceuticals maintains its corporate headquarters in Cambridge, Massachusetts.
주가
$227.32
시가총액
$30.42B
변동 (1일)
-1.47%
변동 (1년)
-52.04%
국가
US
거래 Alnylam Pharmaceuticals, Inc. (ALNY)
카테고리
Healthcare
Alnylam Pharmaceuticals, Inc. (ALNY)의 매출
Jun 2026 기준 매출 TTM: $4.80B
Alnylam Pharmaceuticals, Inc.의 최신 재무 보고서에 따르면 회사의 현재 수익 (TTM)은 $4.80B입니다. 2024년에 회사는 $2.25B의 수익을 올렸으며 이는 2023년의 $1.83B 대비 증가입니다. 수익은 상품이나 서비스를 판매하여 얻은 총 수입을 의미합니다. 수익과는 달리 비용이 차감되지 않습니다.
Alnylam Pharmaceuticals, Inc.의 수익 기록 (2002 ~ 2026)
매년 말 매출
| 연도 | 매출 | 변화 |
|---|---|---|
| 2026 (TTM) | $4.80B | 29.36% |
| 2025 | $3.71B | 65.19% |
| 2024 | $2.25B | 22.97% |
| 2023 | $1.83B | 76.23% |
| 2022 | $1.04B | 22.88% |
| 2021 | $844.29M | 71.31% |
| 2020 | $492.85M | 124.28% |
| 2019 | $219.75M | 193.36% |
| 2018 | $74.91M | -16.69% |
| 2017 | $89.91M | 90.66% |
| 2016 | $47.16M | 14.75% |
| 2015 | $41.10M | -18.72% |
| 2014 | $50.56M | 7.20% |
| 2013 | $47.17M | -29.31% |
| 2012 | $66.73M | -19.37% |
| 2011 | $82.76M | -17.28% |
| 2010 | $100.04M | -0.49% |
| 2009 | $100.53M | 4.54% |
| 2008 | $96.16M | 88.94% |
| 2007 | $50.90M | 89.00% |
| 2006 | $26.93M | 371.13% |
| 2005 | $5.72M | 33.61% |
| 2004 | $4.28M | 2,330.68% |
| 2003 | $176.00K | 0.00% |
| 2002 | 0.00 | 0.00% |
유사 기업 또는 경쟁사의 매출
| 회사 | 매출 | 매출 차이 | 국가 |
|---|---|---|---|
| $12.62B | 162.78% |
US
|
|
| $2.23B | -53.62% |
US
|
|
| $15.74B | 227.72% |
AU
|
|
| $6.02B | 25.33% |
NL
|
|
| - | - |
CH
|
